Sentences with phrase «patients randomised»

Of the 1,952 patients randomised in ION - 1, ION - 2 and ION - 3, 1,886 patients (96.6 %) achieved the primary efficacy endpoint of SVR12.

Of 592 patients randomised and treated, 92 % had GT - 3 HCV, 67 % were male, 84 % white, 53 % treatment experienced, 62 % had non-CC IL28B genotypes and 37 % had cirrhosis.

Not exact matches

In July 2000 patients were randomised to a control group and an intervention group.

Effects of remote, retroactive intercessory prayer on outcomes in patients with bloodstream infection: randomised controlled trial.

He contributes to other large - scale clinical trials including SAVE (evaluating whether treatment of obstructive sleep apnoea with continuous positive airways pressure can reduce the incidence of serious CV events in patients with established CVD), and CREDENCE, a randomised, double - blind, placebo - controlled trial assessing whether canagliflozin can slow the progression of diabetic nephropathy in patients with type 2 diabetes.

Pre-specified subgroup analyses were performed.Six randomised controlled trials were included in this IPDMA, encompassing data from 787 patients (n = 390 for nifedipine; n = 397 for placebo / no treatment).

Long - term treatment with probiotics in primary care patients with irritable bowel syndrome — a randomised, double - blind, placebo controlled trial.

In areas where the patient's choice has a profound effect on outcome, random comparisons eliminating choice will give unreliable estimates of true differences.14 Therefore, in the Netherlands, where choosing between home or hospital birth is an integral feature of the system, randomised controlled trials between home birth and hospital birth would not produce generalisable results even if it were possible to mount such trials.

Galeterone will now be tested in a phase III trial in which patients with metastatic CRPC with the AR - V7 variant will be randomised to receive either galeterone or enzalutamide.

This is due to a randomised trial with 215 eligible patients performed between 1989 and 1991, which showed a significant increase in severe thrombocytopenia, severe anemia, pulmonary complications and toxic deaths when granulocyte - macrophage CSFs (GM - CSFs) were used during concurrent chemo - radiotherapy.

In a linked Comment, Dr Juan Pedro - Botet, Hospital del Mar, and Dr Juan Rubiés - Prat, Universitat Autònoma de Barcelona, Barcelona, Spain, write: «Muscle - related adverse event rates are often argued to be low in randomised controlled trials owing to patient selection.

Patients were randomised into eight treatment groups: a single dose regimen of 200, 300 or 500 mg inclisiran, or placebo; or a two dose regimen of 100, 200 or 300 mg inclisiran, or placebo, at days one and 90.

The phase III CONVERT trial enrolled 547 patients with limited - stage SCLC for concurrent chemo - radiotherapy who were randomised to once - daily or twice - daily radiotherapy.

These patients were randomised to receive, or not receive, chemotherapy.

Fred Hayden of the University of Virginia at Charlottesville says both Tamiflu and placebo patients in the randomised controlled trials were also on paracetamol (acetaminophen), so the two were indeed compared.

«If we find that lymphoscintigrams using tilmanocept are at least as good as the conventional radiocolloid tracer in identification and visualization of sentinel nodes, we would like to see a randomised clinical trial involving large numbers of patients,» says Prof de Bree.

One was a case report of successfully re-implanting an ectopic pregnancy into a patient's womb and another was a randomised trial about treating recurrent miscarriage.

«Currently, the NHS Breast Cancer Screening program in the UK is undertaking a large randomised controlled trial in patients aged 71 - 73 in order to evaluate the effects of screening on breast cancer incidence and mortality.

Patients were randomised to receive CCBT or physiotherapy over an 18 month period for eight weeks.

In the randomised study, all patients with social anxiety disorder were treated with the same dosage of escitalopram for nine weeks, but only one group was correctly informed about the drug and its effectiveness.

During 2008 to 2011, 951 patients were randomised to ipilimumab or placebo.

Due to a wide range of factors including each patient's pre-held beliefs about what might or might not be successful for them, it was very difficult to get patients to agree to be randomised to surgery or non-surgery.

Following first - line treatment, patients experiencing disease progression were randomised 1:1 to receive second - line treatment of FOLFOX plus cetuximab (Arm A; n = 74) or sole FOLFOX (Arm B; n = 79).

The other 200 patients were randomised to dose - escalated external beam radiation therapy (DE-EBRT) and received an additional 32 Gy of external beam radiation to achieve a total prostate dose of 78 Gy.

CT - P13 has previously demonstrated pharmacokinetic (PK) equivalence to INX in the PLANETAS trial, a randomised double - blind, parallel group study of 250 patients with AS, and was recently approved by the European Medicines Agency.

Results from a randomised controlled trial to compare the use of permanent radioactive implants (brachytherapy) with dose - escalated external beam radiotherapy in patients with prostate cancer show that the men who received brachytherapy were twice as likely to be cancer - free five years later.

Analysis of data from nine randomised trials involving 6756 patients (1729 older than 80 years of age) showed that alteplase treatment significantly increased the odds of a good stroke outcome (no significant disability 3 - 6 months after stroke), with faster treatment offering the best chance of recovery.

The trial included 305 patients from 16 countries who were randomised 1:1 to pembrolizumab or chemotherapy.

Patients were randomised in a 1:1:1 fashion to receive celecoxib (100 - 200 mg twice a day), ibuprofen (600 - 800 mg three times a day), or naproxen (375 - 500 mg twice a day) with matching placebos.

RELAX - AHF was a randomised, double blind controlled trial that evaluated the effects of a 48 - hour infusion of the intravenous drug, serelaxin, on clinical outcomes in 1 161 patients admitted to hospital for acute heart failure.

Patients were randomised 1:1 to receive therapy with ceritinib or chemotherapy (pemetrexed or docetaxel).

Twenty - six accredited surgeons from 24 sites in Australia and New Zealand randomised 475 patients with T1 - T3 rectal adenocarcinoma less than 15 cm from the anal verge.

Commenting on the trial, Dr Alice Shaw, director of thoracic oncology at the Massachusetts General Hospital Cancer Centre in Boston, US, said: «This is the first randomised study to examine how a second generation ALK inhibitor compares to standard second line chemotherapy in ALK positive patients who failed the standard first line therapy, which currently is crizotinib.»

The KEYNOTE - 45 study randomised 542 patients from 29 countries between November 2014 and November 2015 to either pembrolizumab (200 mg, given intravenously once every three weeks for up to 24 months) or one of three chemotherapy options chosen by study investigators.

«This is the first randomised trial to show that fecal transplantation may be of benefit to patients with hepatic encephalopathy.

The meta - analysis identified 14 randomised studies that evaluated the impact of decision aids for the patient's choice of localised prostate cancer treatment.

Writing in a linked Comment, Dr Daniel J Clauw, Chronic Pain and Fatigue Research Centre, the University of Michigan, USA, says: «The finding that graded exercise therapy is effective even when exercise is not being witnessed and directly guided by a physiotherapist is a substantial advance, since many patients with chronic fatigue syndrome and other functional impairment have difficulty getting to physiotherapy or do not have access to appropriately trained physiotherapists... In summary, findings from this pragmatic randomised controlled trial add to the evidence that straightforward, non-pharmacological therapies can be helpful in the management of symptoms such as fatigue in individuals with chronic fatigue syndrome.

Dr Nakano concluded: «The next step should now be to initiate a randomised controlled trial of statin use in patients with CAD and very low LDL - C levels.

Dr Nakano said: «Many randomised clinical trials, such as Treating to New Targets (TNT) and PROVE IT - TIMI, have shown that aggressive cholesterol lowering with statins improves clinical outcomes in patients with CAD and high LDL - C levels.1, 2 But until now it was not known whether aggressive lipid lowering with statins would also benefit CAD patients with very low LDL - C levels.»

Intensity modulated radiotherapy (IMRT) gives better results than standard radiotherapy in patients with early breast cancer, according to results from a randomised trial presented today (Sunday) to the 2nd Forum of the European Society for Radiotherapy and Oncology (ESTRO).

Patients were assigned to cohorts by BRCA mutation status and randomised 2:1 to receive niraparib 300 mg or placebo once daily.

The only previous study looking at this was much smaller, and rather than picking out all patients with doses greater than 107 % and randomising them, it only included women with larger breasts who are already known to be more likely to have regions of dose above the upper limit.

A total of 71 % of the plans fell into this category, and those patients were randomised between standard 2DRT and IMRT.

Patients were recruited from 16 different healthcare centres across Scania in southern Sweden for the eight - week randomised controlled trial.

There is a randomised clinical trial of 900 patients currently underway, organised by University of Birmingham, which is looking at the comparative risks of the two threads.

Instead of a traditional randomised cohort selected using strict criteria, the new study used specific, representative patients drawn directly from GP practices in which they were receiving care for COPD.

422 patients were randomised 2:2:2:1:1 to tofacitinib 5 or 10 mg twice daily, adalimumab 40 mg subcutaneous injection every 2 weeks, or placebo (advancing to tofacitinib 5 or 10 mg twice - daily at 3 months).

This Phase 2a, randomised, double - blind, placebo - controlled multicentre study included 149 active PsA patients.

Out of a total of 945 patients in 20 different countries [3] who were randomised to receive the combination therapy or one of the drugs alone, those on the combination therapy survived for an average of 11.5 months without their disease progressing, compared, to 6.9 months for patients on nivolumab alone and 2.9 months for those on ipilimumab alone.

Adjuvant lymph - node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph - node field relapse after lymphadenectomy (ANZMTG 01.02 / TROG 02.01): 6 - year follow - up of a phase 3, randomised controlled trial.